ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد

Drug interactions in Rotor syndrome: Substrates for OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3)

Drug interactions in Rotor syndrome: Substrates for OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3)
OATP1B1 (SLCO1B1) OATP1B3 (SLCO1B3)
Statins:
  • Fluvastatin
  • Pitavastatin
  • Rosuvastatin
  • Atorvastatin
  • Pravastatin
  • Cerivastatin
  • Lovastatin
  • Simvastatin

Antibiotics:

  • Benzylpenicillin
  • Cefditoren
  • Cefoperazone
  • Nafcillin
  • Rifampin
  • Cefazolin
  • Caspofungin (antifungal)

Diuretic:

  • Torsemide

Antihypertensives:

  • Valsartan
  • Olmesartan
  • Bosentan
  • Enalapril
  • Temocapril
  • Temocaprilat

Triglyceride-lowering agent:

  • Gemfibrozil

Cholesterol absorption inhibitor:

  • Ezetimibe glucuronide

HIV protease inhibitors[1]:

  • Lopinavir
  • Saquinavir
  • Darunavir

Antidiabetic:

  • Troglitazone sulfate

Anticancers:

  • Atrasentan
  • Karenitecin (BNP1350)
  • Flavopiridol
  • Gimatecan
  • Methotrexate
  • SN-38 (toxic metabolite of irinotecan)

Immunosuppressive agents[2]:

  • Mycophenolate mofetil
  • Cyclosporin A
 Statins:
  • Fluvastatin
  • Pitavastatin
  • Pravastatin
  • Rosuvastatin

Antibiotics:

  • Nafcillin
  • Cefmetazole
  • Cephalexin
  • Cefoperazone
  • Rifampin
  • Cefazolin
  • Cefadroxil
  • Cefditoren
  • Deltorphin II

Antihypertensives:

  • Telmisartan
  • Valsartan
  • Olmesartan
  • Bosentan
  • Ro 48-5033 (bosentan metabolite)
  • Enalapril

Antihistamine:

  • Fexofenadine

Cardioactives:

  • Digoxin
  • Ouabain

HIV protease inhibitor[1]:

  • Saquinavir

Anticancers:

  • Paclitaxel
  • Atrasentan
  • Methotrexate
  • Docetaxel
  • Imatinib
  • SN38 (toxic irinotecan metabolite)

Immunosuppressive agent[2]:

  • Mycophenolate mofetil
Rotor syndrome is caused by pathogenic variants in both SLCO1B1 and SLCO1B3, which encode OATP1B1 and OATP1B3, respectively. Affected individuals are at risk for toxicity from drugs that require these transporters for efficient biliary excretion, including muscle toxicity from statins and toxic effects of anticancer drugs. Within each category, the drugs that are predicted to have the most impaired biliary excretion are listed first (based on affinity for the transporter, when such information is available).
HIV: human immunodeficiency virus; OATP1B: organic anion transporter proteins 1B.
References:
  1. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112.
  2. Shu Q, Fan Q, Hua B, et al. Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 -106G>A genetic polymorphisms on mycophenolic acid levels and adverse reactions in Chinese autoimmune disease patients. Pharmgenomics Pers Med 2021; 14:713.

Prepared with additional information from:

  • Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 2013; 28:4.
  • Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158:693.
Graphic 147696 Version 1.0